Pharsight

Organon patents expiration

1. Implanon patents expiration

IMPLANON's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8888745 ORGANON Applicator for inserting an implant
Aug, 2026

(2 years from now)

US10821277 ORGANON Kit for and method of assembling an applicator for inserting an implant
May, 2027

(3 years from now)

US8722037 ORGANON X-ray visible drug delivery device
Sep, 2027

(4 years from now)

US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(6 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

IMPLANON family patents

Family Patents

2. Singulair patents expiration

SINGULAIR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8007830 ORGANON Granule formation
Oct, 2022

(11 months ago)

Drugs and Companies using MONTELUKAST SODIUM ingredient

Market Authorisation Date: 26 July, 2002

Treatment: NA

Dosage: GRANULE;ORAL

How can I launch a generic of SINGULAIR before it's drug patent expiration?
More Information on Dosage

SINGULAIR family patents

Family Patents

3. Zetia patents expiration

ZETIA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7030106 ORGANON Sterol absorption inhibitor compositions
Jan, 2022

(1 year, 8 months ago)

US7030106

(Pediatric)

ORGANON Sterol absorption inhibitor compositions
Jul, 2022

(1 year, 2 months ago)

US7612058 ORGANON Methods for inhibiting sterol absorption
Oct, 2025

(2 years from now)

US7612058

(Pediatric)

ORGANON Methods for inhibiting sterol absorption
Apr, 2026

(2 years from now)

Drugs and Companies using EZETIMIBE ingredient

Market Authorisation Date: 25 October, 2002

Treatment: To reduce elevated total-c, ldl-c, apo b and non-hdl-c in patients with primary hyperlipidemia by administration of ezetimibe alone or in combination with a statin or with fenofibrate; Reduction of el...

Dosage: TABLET;ORAL

How can I launch a generic of ZETIA before it's drug patent expiration?
More Information on Dosage

ZETIA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic